Reseña del libro "Pharmacogenomics (en Inglés)"
Pharmacogenomics represents one of the most important developments in modern medicine because it seeks to explain why individuals can respond differently to the same medication. Although medicines are developed and prescribed on the basis of evidence from large populations, patients do not share identical genetic backgrounds, physiological characteristics, environmental exposures, or patterns of drug metabolism. As a result, a medicine that is effective for one individual may be less effective, produce an unexpected reaction, or cause serious adverse effects in another. Pharmacogenomics seeks to reduce this uncertainty by examining how genetic variation influences drug response. The development of genomics has transformed our understanding of human biology and disease. Advances in DNA sequencing, molecular genetics, bioinformatics, computational biology, and clinical laboratory technologies have made it increasingly possible to identify genetic variants associated with drug metabolism, transport, drug targets, therapeutic response, and adverse drug reactions. These discoveries have created opportunities to move beyond a traditional trial-and-error approach toward more individualized prescribing. This book, Pharmacogenomics, provides a comprehensive introduction to the principles, technologies, clinical applications, challenges, and future directions of this rapidly developing field. It is designed to connect fundamental concepts in genetics and pharmacology with their practical significance in healthcare. The discussion begins with the foundations of human genetics and the human genome before progressing into genetic variation, pharmacokinetics, pharmacodynamics, drug-metabolizing enzymes, transporters, and drug targets. Particular attention is given to important pharmacogenomic genes and pathways, including cytochrome P450 enzymes, human leukocyte antigen genes, drug transporters, drug targets, and genes involved in drug toxicity. The book also examines how pharmacogenomics can contribute to the prevention of adverse drug reactions and the selection and dosing of medications. The clinical applications of pharmacogenomics are discussed across a broad range of medical specialties. These include cardiovascular medicine, oncology, psychiatry, neurology, infectious diseases, gastroenterology, endocrinology, metabolic diseases, rheumatology, immunology, pediatric medicine, and geriatric medicine. These examples demonstrate that pharmacogenomics is not limited to a single therapeutic area but has relevance across many aspects of modern clinical practice. An important theme throughout this book is that genetic information should not be interpreted in isolation. Drug response is influenced by numerous factors, including age, organ function, disease state, drug interactions, environmental exposures, diet, adherence, and other genetic and biological characteristics. The phenomenon known as phenoconversion illustrates how a person's observed drug-metabolizing phenotype may differ from what would be predicted from genotype alone. Consequently, pharmacogenomic information is most valuable when it is integrated with clinical judgment and other patient-specific information. The book also explores the technologies that make pharmacogenomic testing possible. Polymerase chain reaction, microarrays, Sanger sequencing, next-generation sequencing, whole-exome sequencing, whole-genome sequencing, long-read sequencing, and specialized approaches for complex pharmacogenes have expanded the ability to detect clinically relevant genetic variation. Bioinformatics and computational methods are equally important because genetic data must be processed, interpreted, annotated, and translated into clinically meaningful information.
